4.7 Article

Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting

期刊

JOURNAL OF INFECTIOUS DISEASES
卷 221, 期 12, 页码 2018-2025

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiz374

关键词

17D; immunity; neutralizing antibodies; vaccine

资金

  1. National Institute of Allergy and Infectious Diseases [R21 AI135537-01]
  2. National Center for Advancing Translational Science Clinical and Translational Science Awards [UL1 TR000128]
  3. Sunlin and Priscilla Chou Foundation
  4. Oregon National Primate Research Center grant [8P51 OD011092]
  5. Oregon Clinical and Translational Research Institute, Takeda Vaccines [IISR 2016-101586]

向作者/读者索取更多资源

Background. The once-in-a-lifetime recommendation for vaccination against yellow fever virus (YFV) has been controversial, leading to increased scrutiny of the durability of immunity after 17D vaccination. Methods. This is a cross-sectional analysis of 17D vaccinees living in nonendemic Portland, Oregon. Neutralization assays were used to determine YFV immunity. The relationships between 17D immunity and vaccination history, demographics, and travel were evaluated using nominal logistic regression. Results. Seventy-one of 92 (77.2%) subjects were YFV seropositive (90 percent plaque reduction neutralization test >= 1:0) at all timepoints, and 24 of 38 (63.8%) were YFV seropositive at >= 10 years after single-dose vaccination. No relationship was found between YFV immunity and time in endemic countries, other flavivirus immunity, or demographics. Subjects were most likely to become seronegative between 3 and 12 years postvaccination (logistic regression, odds ratio [OR] = 1.75; 95% confidence interval [CI], 1.12-2.73). A comparison of our results and 4 previous studies of YFV nonendemic vaccinees found that overall, 79% (95% CI, 70%-86%) of vaccinees are likely to be seropositive >= 10 years postvaccination. Conclusions. These results suggest that 1 in 5 17D vaccinees will lack neutralizing antibodies at similar to 10 years postvaccination, and a booster vaccination should be considered for nonendemic vaccinees before travel to regions where there is a high risk of YFV transmission.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据